Seeking Alpha

Celsion (CLSN -6.4%) slides after Brean Capital cut the shares to Sell earlier today. Brean says...

Celsion (CLSN -6.4%) slides after Brean Capital cut the shares to Sell earlier today. Brean says in a note to clients that the stock has ramped up significantly due to heightened expectations over clinical trials for it's RFAT liver cancer treatment, which is expected this month. The firm calls it "a highly binary event in 1Q13 that, in our view, will define whether or not the company remains viable thereafter." This caution is shared by a Seeing Alpha contributor: Recalculating Celsion's Upcoming Results.
Comments (1)
  • Rod Rose
    , contributor
    Comments (6) | Send Message
     
    Really? Elsewhere on Seeking Alpha is this:

     

    Celsion Announces Phase III HEAT Study of ThermoDox(R) in Primary Liver Cancer Reaches Target Number of Events for Unblinding

     

    Paraphrasing, Michael H. Tardugno, Celsion's President and Chief Executive Officer, said, "The positive implications of this study, for patients and their families, the healthcare community, our investors and employees, cannot be overestimated."

     

    Oopsie, Brean ...
    17 Jan 2013, 12:26 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|